Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polychemotherapy versus standard care to induce remission in newly diagnosed type 2 diabetes mellitus
2018-000833-12Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of metformin, pioglitazone, sitagliptin and empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Complete remission of type 2 diabetes at 52 weeks. Started Sep 2018; status: completed.
02
Drugs
metforminpioglitazonesitagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-000833-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000833-12.